CATALYST PHARMACEUTICALS, INC. | Business Contracts

Form of Transition Services Agreement between Eisai, Inc., a subsidiary of Eisai, and the Company (certain identified information has been excluded from the exhibit because it... (Filed With SEC on December 22, 2022)

Asset Purchase Agreement by and between Eisai and the Company, dated as of December 17, 2022 (certain identified information has been excluded from the exhibit because it both (i)... (Filed With SEC on December 22, 2022)

Form of Supply Agreement between Eisai and the Company (certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) would be... (Filed With SEC on December 22, 2022)

License & Supply Agreement, dated as of June 28, 2021, between DyDo Pharma, Inc. and the Company (Certain identified information has been excluded from the exhibit because it both... (Filed With SEC on June 30, 2021)

Fifth Amendment to Lease Agreement, dated effective as of May 7, 2020, among the Company and PRII 355 Alhambra Circle, LLC (Certain identified information has been excluded from... (Filed With SEC on May 13, 2020)

Amendment No. 1 to Collaborative Agreement with Endo for generic Sabril (certain identified information has been excluded from this exhibit because it is both (i) not material and... (Filed With SEC on May 10, 2019)

Amendment No. 8 to Employment Agreement between the Company and Patrick J. McEnany, dated September 8, 2022 (Filed With SEC on September 9, 2022)

Settlement Agreement, dated July 11, 2022, by and between the Company and SERB SA, on the one hand, and Jacobus Pharmaceutical Company Inc., PantherRx Specialty LLC, and Panther... (Filed With SEC on July 12, 2022)

License and Asset Purchase Agreement, dated as of July 11, 2022, by and between Jacobus Pharmaceutical Company, Inc. and the Company (Filed With SEC on July 12, 2022)

Description of the Companys Capital Stock (Filed With SEC on March 16, 2022)

Description of the Companys Capital Stock (Filed With SEC on March 15, 2021)

Amendment No. 7 to Employment Agreement between the Company and Patrick J. McEnany, dated September 9, 2020 (Filed With SEC on September 11, 2020)

License & Supply Agreement, dated as of August 14, 2020, between KYE Pharmaceuticals, Inc. and the Company (Certain identified information has been excluded from the exhibit... (Filed With SEC on August 20, 2020)

Description of the Companys Capital Stock (Filed With SEC on March 16, 2020)

Amendment No. 2 to Rights Agreement, dated as of August 28, 2019, between Catalyst Pharmaceuticals, Inc. and Continental Stock Transfer and Trust Company, as Rights Agent (Filed With SEC on August 30, 2019)

Amendment No. 2 to License Agreement, made and entered into effective as of May 29, 2019, by and between BioMarin and the Company (certain identified information has been excluded... (Filed With SEC on May 30, 2019)

CATALYST PHARMACEUTICALS, INC. (16)